Zydus Lifesciences has announced a proposal to buy back up to 95,65,217 equity shares, representing 0.95% of its total paid-up equity share capital. The buyback will be executed at a price of ₹1,150 per share, with a total aggregate outlay not exceeding ₹1,100 crore. This initiative, approved by the Board on May 19, 2026, will be conducted through the tender offer route for all eligible shareholders.
Buyback Details and Pricing
In a recent board meeting held on May 19, 2026, Zydus Lifesciences formally approved a plan to buy back 95,65,217 equity shares. The company has set the buyback price at ₹1,150 per share, which is a significant move to return value to shareholders. The total expenditure for this buyback is capped at ₹1,100 crore, excluding transaction-related costs such as brokerage, taxes, and other incidental expenses.
Shareholder Participation and Timeline
The buyback will be conducted on a proportionate basis using the tender offer mechanism. This offer is open to all existing shareholders and beneficial owners, including the promoter group, who hold shares as of the designated Record Date. The company has fixed May 29, 2026, as the record date to determine the eligibility of shareholders to participate in this process.
Strategic Context
This buyback represents approximately 5.16% of the company’s standalone paid-up equity share capital and free reserves as of March 31, 2026. The Board has also constituted a Buyback Committee, which is empowered to oversee the implementation of the process and make necessary decisions to ensure the buyback is conducted smoothly and in compliance with the established regulatory framework.
Source: BSE
